Circulating endothelial cells and serum visfatin are indicators of cardiovascular disease risk in psoriasis patients

Abstract

a b s t r a c tBackground: Cardiovascular risk in psoriasis (PS) appears to be dependent on disease severity. Circulating endothelial cell (CEC) counts appear to be elevated in numerous conditions associated with endothelial dysfunction including chronic immune-mediated inflammatory disorders. Adipokines could serve as a missing link between PS and comorbidities Aim: To evaluate the numbers of CECs and serum visfatin levels in PS patients in comparison to controls to investigate their possible role in increased cardiovascular disease (CVD) risk. Methods: Twenty-five PS patients and 15 healthy individuals were recruited. CECs numbers were detected in peripheral blood samples through studying CD146 and CD45 expression by flow cytometry. Serum visfatin levels were detected by enzyme-linked immunosorbent assay. Results: There was a statistically significant increase in CEC numbers and serum visfatin levels in PS patients compared to controls (p < 0.001) with significant positive correlations between serum visfatin levels and PS severity and numbers of CECs in PS patients. Also, there was a significant difference in numbers of CECs (p 0.001) and serum visfatin levels (p 0.001) between CVD risk positive and CVD risk negative psoriasis patients. Conclusion: Both numbers of CECs and serum visfatin levels were increased in PS patients compared with controls and also increased in CVD risk positive when compared with CVD risk negative PS patients. Both correlated with disease severity suggesting the possibility of increased CVD risk in PS patients.

Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis

“…18,19,23,24,[26][27][28][29][30][31][32] The pooled results demonstrated that visfatin levels were significantly higher in the psoriasis group than in the control group (SMD ¼ 0.90, 95% CI 0.52, 1.28, P < 0.001) (Figure 2). 18,19,23,24,[26][27][28][29][30][31][32] Cochran's Q test showed significant heterogeneity among these included studies (I 2 ¼ 84.2%, P < 0.001). Subgroup analyses were performed due to the existence of heterogeneity.…”

“…As shown in Figure 1, a total of 11 casecontrol studies were eligible to be included in the meta-analysis, with 448 patients with psoriasis and 377 controls. 18,19,23,24,[26][27][28][29][30][31][32] These studies were published from 2012 to 2020 and were undertaken in Asia, Africa and Europe. In the study quality assessment, 10 studies had a NOS score !7.…”

“…Sensitivity analysis of studies included in a meta-analysis to evaluate the relationship between psoriasis and serum visfatin levels. 18,19,23,24,[26][27][28][29][30][31][32] Figure 4. Funnel plot of studies included in a meta-analysis to evaluate the relationship between psoriasis and serum visfatin levels.…”

“…SMD, standard mean difference. 18,19,23,24,[26][27][28][29][30][31][32] production of inflammatory cytokines. 18 PBEF is upregulated in the context of several chronic inflammatory diseases, 37 and it is involved in delaying neutrophil apoptosis in the context of inflammation.…”

“…Characteristics of eligible studies included in this meta-analysis to evaluate the relationship between psoriasis and serum visfatin levels 18,19,23,24,[26][27][28][29][30][31][32]. Author…”